https://scholars.lib.ntu.edu.tw/handle/123456789/523431
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHING-YAO YANG | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.contributor.author | PAN-CHYR YANG | en_US |
dc.creator | Yang C.-Y.;Yang J.C.-H.;Pan-Chyr Yang | - |
dc.date.accessioned | 2020-12-02T02:33:06Z | - |
dc.date.available | 2020-12-02T02:33:06Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0066-4219 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078406929&doi=10.1146%2fannurev-med-051718-013524&partnerID=40&md5=e2308d337f1fe3f69ce5dcb80b32f1f9 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/523431 | - |
dc.description.abstract | The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to personalized precision medicine. In this century, extraordinary advances have been made in the management of advanced and metastatic non-small cell lung cancer, especially in the development of small molecules targeting specific tyrosine kinase receptors and immune checkpoint inhibitors. These developments have led to a significant improvement in survival for lung cancer patients with metastatic disease. Now, the core guidelines to treat non-small cell lung cancer are based on the identification of targetable driver mutations and immune checkpoints. Continued investigations of newly identified druggable genetic alterations, explorations of biomarkers of immune checkpoint inhibitors, development of next-generation immunotherapy, and optimization of combination therapy are necessary to provide better treatment outcomes for lung cancer patients in the future. ? 2020 by Annual Reviews. All rights reserved. | - |
dc.publisher | Annual Reviews Inc. | - |
dc.relation.ispartof | Annual Review of Medicine | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | anaplastic lymphoma kinase; antineoplastic agent; B Raf kinase; epidermal growth factor receptor; immune checkpoint inhibitor; immunological antineoplastic agent; unclassified drug; anaplastic lymphoma kinase; angiogenesis inhibitor; B Raf kinase; epidermal growth factor receptor; programmed death 1 ligand 1; programmed death 1 receptor; protein kinase inhibitor; advanced cancer; c ros1 oncogene; cancer immunotherapy; cancer prognosis; cancer survival; gene mutation; human; lung adenocarcinoma; molecularly targeted therapy; non small cell lung cancer; oncogene; personalized medicine; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; randomized controlled trial (topic); Review; genetics; lung adenocarcinoma; lung tumor; non small cell lung cancer; personalized medicine; squamous cell carcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | - |
dc.title | Precision Management of Advanced Non-Small Cell Lung Cancer | en_US |
dc.type | review | en |
dc.identifier.doi | 10.1146/annurev-med-051718-013524 | - |
dc.identifier.pmid | 31986082 | - |
dc.identifier.scopus | 2-s2.0-85078406929 | - |
dc.relation.pages | 117-136 | - |
dc.relation.journalvolume | 71 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | review | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Biomedical Electronics and Bioinformatics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0003-4927-4814 | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.orcid | 0000-0001-6330-6048 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。